PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Insulin Glargine - Toujeo - Diabetes Mellitus
PAD Profile : Insulin Glargine - Toujeo - Diabetes Mellitus
Keywords :
High-strength insulins, high strength insulins, lipohypertrophy, cutaneous amyloidosis
Brand Names Include :
Toujeo
Traffic Light Status
Status 1 of 1.
Status :
Blue
Important
Formulations :
- Pre-filled pen
Important Information :
Initiation by diabetes consultants or GPs with a specialist interest in diabetes. For use in poorly controlled patients.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Comments :
No comments returned.
Documents :
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Dapagliflozin
- Exenatide
- Insulin detemir
- Liraglutide
- Pioglitazone hydrochloride
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Empagliflozin
- Xultophy
- Metformin hydrochloride
- Dulaglutide
- Insulin glargine - Abasaglar
- Insulin degludec
- Insulin aspart - NovoRapid
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Gliclazide
- Acarbose
- Insulin Aspart - Trurapi
- Repaglinide
- Glimepiride
- Glipizide
- Glibenclamide
- Tolbutamide
- Albiglutide
- Insulin pump - Type 1 diabetes
- Semaglutide
- Ertugliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Glyxambi (Linagliptin/empagliflozin)
- Sotagliflozin
- Semaglutide (oral)
- Tirzepatide
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Alogliptin/metformin
- Linagliptin/metformin
- Empagliflozin/metformin
- Canagliflozin/metformin
- Dapagliflozin/metformin
- Saxagliptin/dapagliflozin
- Metformin hydrochloride/pioglitazone
- Diazoxide
- Glucose
- Soluble insulin - Hypurin porcine neutral
- Insulin Lispro - Lyumjev
- Insulin Lispro - Humalog
- Insulin Aspart - Fiasp
- Soluble insulin - Humulin R
- Soluble insulin - Humulin S
- Soluble insulin - Actrapid
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Isophane (neutral insulin) - hypurin porcine 30/70
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Isophane Insulin - Humulin I
Other Indications
Additional Documents
Type
Document
Review Date
Policy Statement
01 February 2019
Safety Information
Committee Recommendations
Date
Committee Name
Narrative
14 July 2021
Surrey Heartlands Medicines Safety Committee (MSC)
MHRA Safety Alert
Cutaneous amyloidosis can be considered as a differential diagnosis to lipodystrophy when a patient presents with subcutaneous lumps at an insulin injection site. Healthcare professionals are advised to ensure that all people who inject insulin are taught to check for signs of developing cutaneous amyloidosis or lipohypertrophy and that they should report any abnormalities to their healthcare professional.
Refer to the Cutaneous amyloidosis Guidance for Healthcare Professionals below
03 February 2016
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommends the use of Toujeo (insulin glargine 300units/ml) in type 2 diabetes in the following circumstances:
A: To be initiated by diabetes consultants or those GPs with specialist interest in diabetes, only in those poorly controlled patients:
Who do not reach their target HbA1c because of significant hypoglycaemia
OR
Who experience significant hypoglycaemia on Neutral Protamine Hagedorn (NPH) and insulin detemir or glargine (100units/ml) irrespective of the level of HbA1c OR
Who cannot use the device needed to inject NPH and insulin detemir or glargine (100units/ml) but who could administer their own insulin safely and accurately if a switch to one of the long acting insulin analogues was made OR
Who need help from a carer or healthcare professional to administer insulin injections and for whom having a 3 hour window for daily administration is essential.
B: For those patients currently receiving Humulin R U-500, consider switch to Toujeo
Associated BNF Codes
06. Endocrine System
06.01.01. Insulin